Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015

D Mehta, R Jackson, G Paul, J Shi… - Expert opinion on …, 2017 - Taylor & Francis
Introduction: There are dozens of drugs in development for AD with billions of dollars
invested. Despite the massive investment in AD drugs and a burgeoning pipeline, there …

Alzheimer's disease: experimental models and reality

E Drummond, T Wisniewski - Acta neuropathologica, 2017 - Springer
Experimental models of Alzheimer's disease (AD) are critical to gaining a better
understanding of pathogenesis and to assess the potential of novel therapeutic approaches …

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease

A Bejanin, DR Schonhaut, R La Joie, JH Kramer… - Brain, 2017 - academic.oup.com
Neuropathological and in vivo studies have revealed a tight relationship between tau
pathology and cognitive impairment across the Alzheimer's disease spectrum. However, tau …

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

SL DeVos, RL Miller, KM Schoch, BB Holmes… - Science translational …, 2017 - science.org
Accumulation of hyperphosphorylated tau directly correlates with cognitive decline in
Alzheimer's disease and other primary tauopathies. One therapeutic strategy may be to …

[HTML][HTML] Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease

A Nobili, EC Latagliata, MT Viscomi… - Nature …, 2017 - nature.com
Alterations of the dopaminergic (DAergic) system are frequently reported in Alzheimer's
disease (AD) patients and are commonly linked to cognitive and non-cognitive symptoms …

Necroptosis activation in Alzheimer's disease

A Caccamo, C Branca, IS Piras, E Ferreira… - Nature …, 2017 - nature.com
Alzheimer's disease (AD) is characterized by severe neuronal loss; however, the
mechanisms by which neurons die remain elusive. Necroptosis, a programmed form of …

[HTML][HTML] Amyloid precursor protein and endosomal–lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease

RA Nixon - The FASEB Journal, 2017 - ncbi.nlm.nih.gov
Abnormalities of the endosomal–lysosomal network (ELN) are a signature feature of
Alzheimer's disease (AD). These include the earliest known cytopathology that is specific to …

Targeting tumor necrosis factor alpha for Alzheimer's disease

B Decourt, DK Lahiri… - Current Alzheimer …, 2017 - ingentaconnect.com
Alzheimer's disease (AD) affects an estimated 44 million individuals worldwide, yet no
therapeutic intervention is available to stop the progression of the dementia …

[PDF][PDF] Scalable production of iPSC-derived human neurons to identify tau-lowering compounds by high-content screening

C Wang, ME Ward, R Chen, K Liu, TE Tracy, X Chen… - Stem cell reports, 2017 - cell.com
Lowering total tau levels is an attractive therapeutic strategy for Alzheimer's disease and
other tauopathies. High-throughput screening in neurons derived from human induced …

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

P Novak, R Schmidt, E Kontsekova, N Zilka… - The Lancet …, 2017 - thelancet.com
Background Neurofibrillary pathology composed of tau protein is a main correlate of
cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting …